← 產業報告目錄
Tumor Treatment Drug Industry Research Report 2026
出版商 APO Research產業別 Healthcare & Life Sciences出版日期 2026-01-02頁數 139報告編號 APO-2895d10ff8
授權報價
| Single User | $2,950 USD |
| Multi User | $4,430 USD |
| Enterprise | $5,900 USD |
報告摘要
The global Tumor Treatment Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Tumor Treatment Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Tumor Treatment Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Tumor Treatment Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Tumor Treatment Drug include Astellas, Biogen Idec, Bristol-Myers Squibb, Celgene, Gilead Sciences, Ipsen, Merck & Co., Otsuka and AstraZeneca, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Tumor Treatment Drug market in terms of revenue (US$ million) and, where applicable, service volume (Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Tumor Treatment Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Tumor Treatment Drug Market by Company
Astellas
Biogen Idec
Bristol-Myers Squibb
Celgene
Gilead Sciences
Ipsen
Merck & Co.
Otsuka
AstraZeneca
AbbVie
Amgen
Bayer
Pfizer
Eli Lilly
Roche
Merck KGaA
Novartis
Johnson & Johnson
Sanofi
Teva
Eisai
Takeda
Tumor Treatment Drug Segment by Type
Immunotherapy (Biologic Therapy)
Chemotherapy
Hormonal Therapy
Targeted Therapy
Others
Tumor Treatment Drug Segment by Application
Respiratory/Lung Cancer
Prostate Cancer
Breast Cancer
Gastrointestinal Cancer
Blood Cancer
Others
Tumor Treatment Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Treatment Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tumor Treatment Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Treatment Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Tumor Treatment Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
目錄 Table of Contents
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Tumor Treatment Drug by Type
2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
2.2.2 Immunotherapy (Biologic Therapy)
2.2.3 Chemotherapy
2.2.4 Hormonal Therapy
2.2.5 Targeted Therapy
2.2.6 Others
2.3 Tumor Treatment Drug by Application
2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
2.3.2 Respiratory/Lung Cancer
2.3.3 Prostate Cancer
2.3.4 Breast Cancer
2.3.5 Gastrointestinal Cancer
2.3.6 Blood Cancer
2.3.7 Others
2.4 Assumptions and Limitations
3 Tumor Treatment Drug Breakdown Data by Type
3.1 Global Tumor Treatment Drug Historic Market Size by Type (2021-2026)
3.2 Global Tumor Treatment Drug Forecasted Market Size by Type (2027-2032)
4 Tumor Treatment Drug Breakdown Data by Application
4.1 Global Tumor Treatment Drug Historic Market Size by Application (2021-2026)
4.2 Global Tumor Treatment Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
5.1 Global Tumor Treatment Drug Market Perspective (2021-2032)
5.2 Global Tumor Treatment Drug Growth Trends by Region
5.2.1 Global Tumor Treatment Drug Market Size by Region: 2021 VS 2025 VS 2032
5.2.2 Tumor Treatment Drug Historic Market Size by Region (2021-2026)
5.2.3 Tumor Treatment Drug Forecasted Market Size by Region (2027-2032)
5.3 Tumor Treatment Drug Market Dynamics
5.3.1 Tumor Treatment Drug Industry Trends
5.3.2 Tumor Treatment Drug Market Drivers
5.3.3 Tumor Treatment Drug Market Challenges
5.3.4 Tumor Treatment Drug Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Tumor Treatment Drug Players by Revenue
6.1.1 Global Top Tumor Treatment Drug Players by Revenue (2021-2026)
6.1.2 Global Tumor Treatment Drug Revenue Market Share by Players (2021-2026)
6.2 Global Tumor Treatment Drug Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Tumor Treatment Drug Head Office and Area Served
6.4 Global Tumor Treatment Drug Players, Product Type & Application
6.5 Global Tumor Treatment Drug Manufacturers Established Date
6.6 Global Tumor Treatment Drug Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Tumor Treatment Drug Market Size (2021-2032)
7.2 North America Tumor Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
7.3 North America Tumor Treatment Drug Market Size by Country (2021-2026)
7.4 North America Tumor Treatment Drug Market Size by Country (2027-2032)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Tumor Treatment Drug Market Size (2021-2032)
8.2 Europe Tumor Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
8.3 Europe Tumor Treatment Drug Market Size by Country (2021-2026)
8.4 Europe Tumor Treatment Drug Market Size by Country (2027-2032)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Tumor Treatment Drug Market Size (2021-2032)
9.2 Asia-Pacific Tumor Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
9.3 Asia-Pacific Tumor Treatment Drug Market Size by Country (2021-2026)
9.4 Asia-Pacific Tumor Treatment Drug Market Size by Country (2027-2032)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Tumor Treatment Drug Market Size (2021-2032)
10.2 South America Tumor Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
10.3 South America Tumor Treatment Drug Market Size by Country (2021-2026)
10.4 South America Tumor Treatment Drug Market Size by Country (2027-2032)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Tumor Treatment Drug Market Size (2021-2032)
11.2 Middle East & Africa Tumor Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
11.3 Middle East & Africa Tumor Treatment Drug Market Size by Country (2021-2026)
11.4 Middle East & Africa Tumor Treatment Drug Market Size by Country (2027-2032)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Astellas
12.1.1 Astellas Company Information
12.1.2 Astellas Business Overview
12.1.3 Astellas Revenue in Tumor Treatment Drug Business (2021-2026)
12.1.4 Astellas Tumor Treatment Drug Product Portfolio
12.1.5 Astellas Recent Developments
12.2 Biogen Idec
12.2.1 Biogen Idec Company Information
12.2.2 Biogen Idec Business Overview
12.2.3 Biogen Idec Revenue in Tumor Treatment Drug Business (2021-2026)
12.2.4 Biogen Idec Tumor Treatment Drug Product Portfolio
12.2.5 Biogen Idec Recent Developments
12.3 Bristol-Myers Squibb
12.3.1 Bristol-Myers Squibb Company Information
12.3.2 Bristol-Myers Squibb Business Overview
12.3.3 Bristol-Myers Squibb Revenue in Tumor Treatment Drug Business (2021-2026)
12.3.4 Bristol-Myers Squibb Tumor Treatment Drug Product Portfolio
12.3.5 Bristol-Myers Squibb Recent Developments
12.4 Celgene
12.4.1 Celgene Company Information
12.4.2 Celgene Business Overview
12.4.3 Celgene Revenue in Tumor Treatment Drug Business (2021-2026)
12.4.4 Celgene Tumor Treatment Drug Product Portfolio
12.4.5 Celgene Recent Developments
12.5 Gilead Sciences
12.5.1 Gilead Sciences Company Information
12.5.2 Gilead Sciences Business Overview
12.5.3 Gilead Sciences Revenue in Tumor Treatment Drug Business (2021-2026)
12.5.4 Gilead Sciences Tumor Treatment Drug Product Portfolio
12.5.5 Gilead Sciences Recent Developments
12.6 Ipsen
12.6.1 Ipsen Company Information
12.6.2 Ipsen Business Overview
12.6.3 Ipsen Revenue in Tumor Treatment Drug Business (2021-2026)
12.6.4 Ipsen Tumor Treatment Drug Product Portfolio
12.6.5 Ipsen Recent Developments
12.7 Merck & Co.
12.7.1 Merck & Co. Company Information
12.7.2 Merck & Co. Business Overview
12.7.3 Merck & Co. Revenue in Tumor Treatment Drug Business (2021-2026)
12.7.4 Merck & Co. Tumor Treatment Drug Product Portfolio
12.7.5 Merck & Co. Recent Developments
12.8 Otsuka
12.8.1 Otsuka Company Information
12.8.2 Otsuka Business Overview
12.8.3 Otsuka Revenue in Tumor Treatment Drug Business (2021-2026)
12.8.4 Otsuka Tumor Treatment Drug Product Portfolio
12.8.5 Otsuka Recent Developments
12.9 AstraZeneca
12.9.1 AstraZeneca Company Information
12.9.2 AstraZeneca Business Overview
12.9.3 AstraZeneca Revenue in Tumor Treatment Drug Business (2021-2026)
12.9.4 AstraZeneca Tumor Treatment Drug Product Portfolio
12.9.5 AstraZeneca Recent Developments
12.10 AbbVie
12.10.1 AbbVie Company Information
12.10.2 AbbVie Business Overview
12.10.3 AbbVie Revenue in Tumor Treatment Drug Business (2021-2026)
12.10.4 AbbVie Tumor Treatment Drug Product Portfolio
12.10.5 AbbVie Recent Developments
12.11 Amgen
12.11.1 Amgen Company Information
12.11.2 Amgen Business Overview
12.11.3 Amgen Revenue in Tumor Treatment Drug Business (2021-2026)
12.11.4 Amgen Tumor Treatment Drug Product Portfolio
12.11.5 Amgen Recent Developments
12.12 Bayer
12.12.1 Bayer Company Information
12.12.2 Bayer Business Overview
12.12.3 Bayer Revenue in Tumor Treatment Drug Business (2021-2026)
12.12.4 Bayer Tumor Treatment Drug Product Portfolio
12.12.5 Bayer Recent Developments
12.13 Pfizer
12.13.1 Pfizer Company Information
12.13.2 Pfizer Business Overview
12.13.3 Pfizer Revenue in Tumor Treatment Drug Business (2021-2026)
12.13.4 Pfizer Tumor Treatment Drug Product Portfolio
12.13.5 Pfizer Recent Developments
12.14 Eli Lilly
12.14.1 Eli Lilly Company Information
12.14.2 Eli Lilly Business Overview
12.14.3 Eli Lilly Revenue in Tumor Treatment Drug Business (2021-2026)
12.14.4 Eli Lilly Tumor Treatment Drug Product Portfolio
12.14.5 Eli Lilly Recent Developments
12.15 Roche
12.15.1 Roche Company Information
12.15.2 Roche Business Overview
12.15.3 Roche Revenue in Tumor Treatment Drug Business (2021-2026)
12.15.4 Roche Tumor Treatment Drug Product Portfolio
12.15.5 Roche Recent Developments
12.16 Merck KGaA
12.16.1 Merck KGaA Company Information
12.16.2 Merck KGaA Business Overview
12.16.3 Merck KGaA Revenue in Tumor Treatment Drug Business (2021-2026)
12.16.4 Merck KGaA Tumor Treatment Drug Product Portfolio
12.16.5 Merck KGaA Recent Developments
12.17 Novartis
12.17.1 Novartis Company Information
12.17.2 Novartis Business Overview
12.17.3 Novartis Revenue in Tumor Treatment Drug Business (2021-2026)
12.17.4 Novartis Tumor Treatment Drug Product Portfolio
12.17.5 Novartis Recent Developments
12.18 Johnson & Johnson
12.18.1 Johnson & Johnson Company Information
12.18.2 Johnson & Johnson Business Overview
12.18.3 Johnson & Johnson Revenue in Tumor Treatment Drug Business (2021-2026)
12.18.4 Johnson & Johnson Tumor Treatment Drug Product Portfolio
12.18.5 Johnson & Johnson Recent Developments
12.19 Sanofi
12.19.1 Sanofi Company Information
12.19.2 Sanofi Business Overview
12.19.3 Sanofi Revenue in Tumor Treatment Drug Business (2021-2026)
12.19.4 Sanofi Tumor Treatment Drug Product Portfolio
12.19.5 Sanofi Recent Developments
12.20 Teva
12.20.1 Teva Company Information
12.20.2 Teva Business Overview
12.20.3 Teva Revenue in Tumor Treatment Drug Business (2021-2026)
12.20.4 Teva Tumor Treatment Drug Product Portfolio
12.20.5 Teva Recent Developments
12.21 Eisai
12.21.1 Eisai Company Information
12.21.2 Eisai Business Overview
12.21.3 Eisai Revenue in Tumor Treatment Drug Business (2021-2026)
12.21.4 Eisai Tumor Treatment Drug Product Portfolio
12.21.5 Eisai Recent Developments
12.22 Takeda
12.22.1 Takeda Company Information
12.22.2 Takeda Business Overview
12.22.3 Takeda Revenue in Tumor Treatment Drug Business (2021-2026)
12.22.4 Takeda Tumor Treatment Drug Product Portfolio
12.22.5 Takeda Recent Developments
13 Report Conclusion
14 Disclaimer
圖表清單 List of Tables & Figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Tumor Treatment Drug Market Size by Type (2021-2026) & (US$ Million)
Table 6. Global Tumor Treatment Drug Revenue Market Share by Type (2021-2026)
Table 7. Global Tumor Treatment Drug Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 8. Global Tumor Treatment Drug Revenue Market Share by Type (2027-2032)
Table 9. Global Tumor Treatment Drug Market Size by Application (2021-2026) & (US$ Million)
Table 10. Global Tumor Treatment Drug Revenue Market Share by Application (2021-2026)
Table 11. Global Tumor Treatment Drug Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 12. Global Tumor Treatment Drug Revenue Market Share by Application (2027-2032)
Table 13. Global Tumor Treatment Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 14. Global Tumor Treatment Drug Market Size by Region (2021-2026) & (US$ Million)
Table 15. Global Tumor Treatment Drug Market Share by Region (2021-2026)
Table 16. Global Tumor Treatment Drug Forecasted Market Size by Region (2027-2032) & (US$ Million)
Table 17. Global Tumor Treatment Drug Market Share by Region (2027-2032)
Table 18. Tumor Treatment Drug Industry Trends
Table 19. Tumor Treatment Drug Industry Drivers
Table 20. Tumor Treatment Drug Industry Opportunities and Challenges
Table 21. Tumor Treatment Drug Market Restraints
Table 22. Global Top Tumor Treatment Drug Players by Revenue (US$ Million) & (2021-2026)
Table 23. Global Tumor Treatment Drug Revenue Market Share by Players (2021-2026)
Table 24. Global Tumor Treatment Drug Industry Players Ranking, 2024 VS 2025 VS 2026
Table 25. Global Key Players of Tumor Treatment Drug, Headquarters and Area Served
Table 26. Global Tumor Treatment Drug Players, Product Type & Application
Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
Table 28. Global Tumor Treatment Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 29. Players Mergers & Acquisitions, Expansion Plans
Table 30. North America Tumor Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 31. North America Tumor Treatment Drug Market Size by Country (2021-2026) & (US$ Million)
Table 32. North America Tumor Treatment Drug Market Size by Country (2027-2032) & (US$ Million)
Table 33. Europe Tumor Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 34. Europe Tumor Treatment Drug Market Size by Country (2021-2026) & (US$ Million)
Table 35. Europe Tumor Treatment Drug Market Size by Country (2027-2032) & (US$ Million)
Table 36. Asia Pacific Tumor Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 37. Asia Pacific Tumor Treatment Drug Market Size by Region (2021-2026) & (US$ Million)
Table 38. Asia Pacific Tumor Treatment Drug Market Size by Country (2027-2032) & (US$ Million)
Table 39. South America Tumor Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 40. South America Tumor Treatment Drug Market Size by Country (2021-2026) & (US$ Million)
Table 41. South America Tumor Treatment Drug Market Size by Country (2027-2032) & (US$ Million)
Table 42. Middle East & Africa Tumor Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 43. Middle East & Africa Tumor Treatment Drug Market Size by Country (2021-2026) & (US$ Million)
Table 44. Middle East & Africa Tumor Treatment Drug Market Size by Country (2027-2032) & (US$ Million)
Table 45. Astellas Company Information
Table 46. Astellas Business Overview
Table 47. Astellas Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 48. Astellas Tumor Treatment Drug Product Portfolio
Table 49. Astellas Recent Developments
Table 50. Biogen Idec Company Information
Table 51. Biogen Idec Business Overview
Table 52. Biogen Idec Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 53. Biogen Idec Tumor Treatment Drug Product Portfolio
Table 54. Biogen Idec Recent Developments
Table 55. Bristol-Myers Squibb Company Information
Table 56. Bristol-Myers Squibb Business Overview
Table 57. Bristol-Myers Squibb Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 58. Bristol-Myers Squibb Tumor Treatment Drug Product Portfolio
Table 59. Bristol-Myers Squibb Recent Developments
Table 60. Celgene Company Information
Table 61. Celgene Business Overview
Table 62. Celgene Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 63. Celgene Tumor Treatment Drug Product Portfolio
Table 64. Celgene Recent Developments
Table 65. Gilead Sciences Company Information
Table 66. Gilead Sciences Business Overview
Table 67. Gilead Sciences Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 68. Gilead Sciences Tumor Treatment Drug Product Portfolio
Table 69. Gilead Sciences Recent Developments
Table 70. Ipsen Company Information
Table 71. Ipsen Business Overview
Table 72. Ipsen Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 73. Ipsen Tumor Treatment Drug Product Portfolio
Table 74. Ipsen Recent Developments
Table 75. Merck & Co. Company Information
Table 76. Merck & Co. Business Overview
Table 77. Merck & Co. Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 78. Merck & Co. Tumor Treatment Drug Product Portfolio
Table 79. Merck & Co. Recent Developments
Table 80. Otsuka Company Information
Table 81. Otsuka Business Overview
Table 82. Otsuka Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 83. Otsuka Tumor Treatment Drug Product Portfolio
Table 84. Otsuka Recent Developments
Table 85. AstraZeneca Company Information
Table 86. AstraZeneca Business Overview
Table 87. AstraZeneca Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 88. AstraZeneca Tumor Treatment Drug Product Portfolio
Table 89. AstraZeneca Recent Developments
Table 90. AbbVie Company Information
Table 91. AbbVie Business Overview
Table 92. AbbVie Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 93. AbbVie Tumor Treatment Drug Product Portfolio
Table 94. AbbVie Recent Developments
Table 95. Amgen Company Information
Table 96. Amgen Business Overview
Table 97. Amgen Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 98. Amgen Tumor Treatment Drug Product Portfolio
Table 99. Amgen Recent Developments
Table 100. Bayer Company Information
Table 101. Bayer Business Overview
Table 102. Bayer Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 103. Bayer Tumor Treatment Drug Product Portfolio
Table 104. Bayer Recent Developments
Table 105. Pfizer Company Information
Table 106. Pfizer Business Overview
Table 107. Pfizer Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 108. Pfizer Tumor Treatment Drug Product Portfolio
Table 109. Pfizer Recent Developments
Table 110. Eli Lilly Company Information
Table 111. Eli Lilly Business Overview
Table 112. Eli Lilly Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 113. Eli Lilly Tumor Treatment Drug Product Portfolio
Table 114. Eli Lilly Recent Developments
Table 115. Roche Company Information
Table 116. Roche Business Overview
Table 117. Roche Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 118. Roche Tumor Treatment Drug Product Portfolio
Table 119. Roche Recent Developments
Table 120. Merck KGaA Company Information
Table 121. Merck KGaA Business Overview
Table 122. Merck KGaA Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 123. Merck KGaA Tumor Treatment Drug Product Portfolio
Table 124. Merck KGaA Recent Developments
Table 125. Novartis Company Information
Table 126. Novartis Business Overview
Table 127. Novartis Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 128. Novartis Tumor Treatment Drug Product Portfolio
Table 129. Novartis Recent Developments
Table 130. Johnson & Johnson Company Information
Table 131. Johnson & Johnson Business Overview
Table 132. Johnson & Johnson Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 133. Johnson & Johnson Tumor Treatment Drug Product Portfolio
Table 134. Johnson & Johnson Recent Developments
Table 135. Sanofi Company Information
Table 136. Sanofi Business Overview
Table 137. Sanofi Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 138. Sanofi Tumor Treatment Drug Product Portfolio
Table 139. Sanofi Recent Developments
Table 140. Teva Company Information
Table 141. Teva Business Overview
Table 142. Teva Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 143. Teva Tumor Treatment Drug Product Portfolio
Table 144. Teva Recent Developments
Table 145. Eisai Company Information
Table 146. Eisai Business Overview
Table 147. Eisai Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 148. Eisai Tumor Treatment Drug Product Portfolio
Table 149. Eisai Recent Developments
Table 150. Takeda Company Information
Table 151. Takeda Business Overview
Table 152. Takeda Revenue in Tumor Treatment Drug Business (2021-2026) & (US$ Million)
Table 153. Takeda Tumor Treatment Drug Product Portfolio
Table 154. Takeda Recent Developments
Table 155. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Tumor Treatment Drug Product Image
Figure 5. Global Tumor Treatment Drug Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 6. Global Tumor Treatment Drug Market Share by Type: 2025 VS 2032
Figure 7. Immunotherapy (Biologic Therapy) Product
Figure 8. Chemotherapy Product
Figure 9. Hormonal Therapy Product
Figure 10. Targeted Therapy Product
Figure 11. Others Product
Figure 12. Global Tumor Treatment Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 13. Global Tumor Treatment Drug Market Share by Application: 2025 VS 2032
Figure 14. Respiratory/Lung Cancer Product
Figure 15. Prostate Cancer Product
Figure 16. Breast Cancer Product
Figure 17. Gastrointestinal Cancer Product
Figure 18. Blood Cancer Product
Figure 19. Others Product
Figure 20. Global Tumor Treatment Drug Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 21. Global Tumor Treatment Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032
Figure 22. Global Tumor Treatment Drug Market Share by Region: 2025 VS 2032
Figure 23. Global Tumor Treatment Drug Market Share by Players in 2025
Figure 24. Global Tumor Treatment Drug Manufacturers Established Date
Figure 25. Global Top 5 and 10 Tumor Treatment Drug Players Market Share by Revenue in 2025
Figure 26. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 27. North America Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 28. North America Tumor Treatment Drug Market Share by Country (2021-2032)
Figure 29. United States Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 30. Canada Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 31. Mexico Tumor Treatment Drug Market Share by Country (2021-2032)
Figure 32. Europe Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 33. Europe Tumor Treatment Drug Market Share by Country (2021-2032)
Figure 34. Germany Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 35. France Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 36. U.K. Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 37. Italy Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 38. Spain Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 39. Russia Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 40. Netherlands Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 41. Nordic Countries Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 42. Asia-Pacific Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 43. Asia-Pacific Tumor Treatment Drug Market Share by Country (2021-2032)
Figure 44. China Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 45. Japan Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 46. South Korea Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 47. India Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 48. India Tumor Treatment Drug Market Share by Country (2021-2032)
Figure 49. Australia Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 50. China Taiwan Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 51. Southeast Asia Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 52. South America Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 53. South America Tumor Treatment Drug Market Share by Country (2021-2032)
Figure 54. Brazil Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 55. Argentina Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 56. Chile Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 57. Colombia Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 58. Peru Tumor Treatment Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 59. Astellas Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 60. Biogen Idec Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 61. Bristol-Myers Squibb Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 62. Celgene Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 63. Gilead Sciences Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 64. Ipsen Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 65. Merck & Co. Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 66. Otsuka Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 67. AstraZeneca Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 68. AbbVie Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 69. Amgen Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 70. Bayer Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 71. Pfizer Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 72. Eli Lilly Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 73. Roche Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 74. Merck KGaA Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 75. Novartis Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 76. Johnson & Johnson Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 77. Sanofi Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 78. Teva Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 79. Eisai Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
Figure 80. Takeda Revenue Growth Rate in Tumor Treatment Drug Business (2021-2026)
提及公司
AstellasBiogen IdecBristol-Myers SquibbCelgeneGilead SciencesIpsenMerck & Co.OtsukaAstraZenecaAbbVieAmgenBayerPfizerEli LillyRocheMerck KGaANovartisJohnson & JohnsonSanofiTevaEisaiTakeda
量子訊息有限公司為 APO Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們